Adam Marcus named interim executive director of Winship Cancer Institute of Emory University

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Adam Marcus was named interim executive director of Winship Cancer Institute of Emory University.

Marcus will assume the role from Walter J. Curran, Jr., while Emory University conducts a national search for Winship’s next executive director.

“We are very fortunate that Dr. Curran will support Dr. Marcus from now until his departure in late January,” Jonathan S. Lewin, executive vice president for health affairs at Emory University and CEO and chair of the board for Emory Healthcare, said in a statement. “They will work together over the next five weeks to ensure a smooth transition in Winship leadership in its research, educational, and clinical missions.”

An advisory committee, with representation from across the Woodruff Health Sciences Center, including Winship leaders, will oversee the executive director search.

Curran, who is also the Lawrence W. Davis Professor and chair of the Department of Radiation Oncology, announced in October that he would be stepping down from his Emory leadership roles to serve as the global chief medical officer of GenesisCare, an international health care provider. He was the first and only radiation oncologist to direct an NCI-designated cancer center.

Marcus, a member of Winship’s executive leadership team and a fellow of the Woodruff Leadership Academy, serves as the associate director for basic research and shared resources at Winship. He is a professor of hematology and medical oncology and holds the Winship 5K Professorship. Marcus is also the scientific director of the Emory Integrated Cellular Imaging Core, one of the Emory Integrated Core Facilities.

Marcus’ research focuses on cancer metastasis, drug development, and image-guided genomics, and he has been continuously funded by NIH since joining the Emory faculty in 2006. He is a principal investigator of five active NIH grants, including a multi-PI R25 Science Education Partnership Award that supports Citizen Science HD. Marcus co-leads Citizen Science HD, an outreach program that provides opportunities for underrepresented learners in STEM.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login